Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis.
MacLean
C H
CH
Mojica
W A
WA
Morton
S C
SC
Pencharz
J
J
Hasenfeld Garland
R
R
Tu
W
W
Newberry
S J
SJ
Jungvig
L K
LK
Grossman
J
J
Khanna
P
P
Rhodes
S
S
Shekelle
P
P
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000178:diet therapy* / Q000188:drug therapy; D015519:Bone Density; D002648:Child; D003924:Diabetes Mellitus, Type 2 / Q000178:diet therapy* / Q000378:metabolism; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology* / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000178:diet therapy* / Q000188:drug therapy; D007674:Kidney Diseases / Q000178:diet therapy* / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000178:diet therapy*; D015201:Meta-Analysis as Topic; D024821:Metabolic Syndrome / Q000178:diet therapy* / Q000378:metabolism; D010024:Osteoporosis / Q000178:diet therapy*; D010919:Placebos; D016032:Randomized Controlled Trials as Topic
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D015525:Fatty Acids, Omega-3; D007166:Immunosuppressive Agents; D010919:Placebos